News

Valneva confirmed its revenue and product sales guidance for 2018 and provided initial product sales guidance for 2019.

Read more

Phase 1 interim results showed an excellent immunogenicity profile after a single-shot vaccination and an acceptable safety profile, supporting…

Read more

Cardiovascular Diseases (CVD) lead to atherosclerosis and heart failure and are prevalent age-related illnesses in humans. In a new study, published…

Read more

Ares Genetics to start EUR 1.3 million TRIPLE-A development project co-funded by Vienna Business Agency, and initiates set-up of R&D and service…

Read more

Valneva announced that it intends to delist from the Vienna Stock Exchange (VSE) in order to focus on the best capital markets for life science…

Read more

The University of Vienna and Medical University of Vienna are extending their successful collaboration with Max F. Perutz Laboratories. Rectors Heinz…

Read more

The agreement grants Gilead exclusive rights to HOOKIPA’s TheraT® and VaxWave® investigational arenavirus-based immunization technologies for the…

Read more

Valneva announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its chikungunya vaccine candidate, VLA1553. …

Read more

In January 2019, the new Managing Director of the Vienna BioCenter Core Facilities GmbH, Daniele Soroldoni, has started his work. Welcome!

Read more

The Vienna Biocenter Summer School provides a unique opportunity for approx. 28 undergraduate students to work side-by-side with leading researchers…

Read more

Strategic collaboration agreement with Sandoz to develop digital anti-infectives platform.

Read more